Also in this playlist...
This transcript is automatically generated
If you're looking at a sector and you're looking at specific companies.
What do you do when a bunch of the competitors actually lowered their expectations yet one of them says.
We're just fine and we're going to raise the bottom end.
Well PerkinElmer is doing that in fact -- Friel was the chairman and CEO of this company that does diagnostic testing at all kinds of interest and lab services.
He is joining us now -- -- Fox Business exclusive from Newton Massachusetts where he is just officially completed.
This acquisition of the 600 million dollar caliper one of the competitors good to see rob thanks for joining us.
-- thanks -- -- being here well this was an all cash deal let me get to this part first because this is an exciting news that you've been able to finally swallowed this whale of caliper but.
-- what they do for you what I understand that you would take on a competitor and that that would of course and add to your sort of strategic relationships but.
What do you -- do to help your bottom line.
So you know we're very excited about the cal for acquisition because it brings first -- all terrific organization.
A long legacy of that innovation.
-- some terrific capabilities.
Really directed it personalized medicine.
It's an -- it's really growing right now and it's.
You know in in the fields of of health care right now it's all about information.
And getting information faster.
So that people can improve outcomes and that's what calpers gonna do for us it's gonna really improve our capabilities.
Around -- personalized medicine area.
I always try to explain to people what Perkin Elmer does -- it's a little difficult but you do this this environmental and diagnostic testing that a lot of government regulation now requires.
For example with the EPA -- test for air and then you'll make sure things are healthier so the people don't think it's -- At board at those.
Bid for example that the health care but costs that happen in this country but what is the most exciting part of your business right now -- it's also the most profitable.
Well I think it's as you said it's it it begins with detection and imaging capability in what we really.
Do well is be able to detect things either on the environmental side as you mentioned in air Warner and and soil and also any human health side and really -- the exciting area right now is what's happening in the area.
A personalized medicine as I said before is revealing -- look at the genetics of the disease.
And then also look at the genetics of the individual.
And -- with that information really being able to.
Work with our customers -- -- the pharmaceutical Biotech area through it come up with better therapeutic responses.
And and that's extremely exciting right now we're seeing nice growth in that area and it's also happens to be one of.
-- more profitable area and rob you've got a developing world here now you've got a developing middle class in China certainly in some of the Brazil.
Rush India areas and so I'm just wondering how big will that be for your business and does it overtake the United States which is -- in a little bit on some levels.
Well yeah that that is an important aspect of our business right now about 25% of our revenue.
Things actually as actually in emerging markets and we continue to see strong growth there.
As you say as their GDP per capita goes up warm warm money is going into health -- we're seeing -- particularly in our newborn screening area.
And and we continue to see great advances there and I think.
Increasingly that's going to be the area at least I would say for the next 1218 months that's gonna be fueling a lot of our growth.
And as we finish up here I just want to know I mean I'd look at the stock -- look at all you're doing your growing get your stock is down 18% over the past year what do investors what does Wall Street have -- here.
Well I think part of it is you as you mentioned earlier it has to do with the sector itself I think there's some concerns about.
Anybody -- exposed to either government -- academic funding.
It is the fact is we have much lower exposure that a number of our peers.
And in fact if you look over the -- couple years I think we've built a very resilient portfolio and it's actually shown in -- Last three quarters and I think if we go in the 2012 we'll start to differentiate ourselves.
From both the top line and a bottom line performance so.
I think in over the long term you'll see PerkinElmer.
Start to differentiate itself from its peer groups and hopefully the stock price wolf recognized.
And that's what you did when you raise the low -- of your guidance for the full year thank you rob good to see you.
Great thank you rob -- with the chairman and CEO of African.
Filter by section